All In Biotech

Free tool

FAERS Monitor: Orbactiv

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 206334 or its brand name (Orbactiv, Oritavancin Diphosphate). Reports on generic versions are filed under their own applications.

Reports

920

Serious

352

38% of reports

Hospitalization

172

Death reported

32

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use175
  • pruritus165
  • urticaria105
  • chills90
  • rash86
  • back pain83
  • dyspnoea81
  • nausea68
  • infusion related reaction62
  • erythema58
  • chest pain56
  • drug ineffective49
  • flushing41
  • vomiting41
  • headache39

Reports by year received

View as table
YearReports
20141
201547
2016159
2017182
2018141
201982
202073
202141
202267
202338
202436
202530
202623

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,239 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal6221.416.81,188
chillsSignal9017.614.41,396
urticariaSignal10514.312.01,299
pruritusSignal1659.88.61,322
flushingSignal419.26.8294
back painSignal838.26.7521
chest painSignal566.95.4280
erythemaSignal586.55.0264
off label useSignal1754.64.0505
rashSignal864.53.7236
dyspnoeaSignal813.32.7129
vomiting412.01.520
nausea682.01.632
headache391.41.05
drug ineffective490.80.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.